How to Use Adjunctive Cariprazine for Major Depressive Disorder
How should clinicians select and start adjunctive cariprazine for adults with major depressive disorder who have had an inadequate response to antidepressant therapy?
Patients with major depressive disorder often remain symptomatic despite an adequate antidepressant trial, creating a practical need for an evidence-based augmentation approach. This guide applies to adults with a current major depressive episode who resemble the trial population studied in Cariprazine for the Adjunctive Treatment of Major Depressive Disorder in Patients With Inadequate Response to Antidepressant Therapy: Results of a Randomized, Double-Blind, Placebo-Controlled Study.
-
Confirm that the patient matches the studied inadequate-response population
Use adjunctive cariprazine only in adults aged 18 to 65 years with DSM-5 major depressive disorder and a current major depressive episode lasting at least 8 weeks and less than 24 months. The study defined inadequate response as less than 50% improvement after 1 to 3 antidepressant therapies of adequate dose and duration during the current episode, with adequate treatment defined as 6 continuous weeks and a dose above the minimum labeled dose for at least 3 of those 6 weeks.
-
Check baseline severity and rule out major exclusions
Before considering this approach, verify depressive severity similar to the trial population, which required an HDRS17 total score of at least 22 and an apparent sadness item score of at least 2. Do not apply this workflow to patients with more than 3 antidepressant failures in the current episode, a current psychiatric diagnosis other than major depressive disorder, a history of manic or hypomanic episodes, a YMRS score of at least 12, substance-related disorders in the past 3 months, or suicide risk or attempt in the past year.
-
Keep one antidepressant in place at the same dose
Adjunctive cariprazine in this study was added to an ongoing antidepressant that patients continued at the baseline dose throughout treatment. If a patient is taking more than 1 antidepressant, this trial required discontinuation of all but 1 antidepressant before baseline.
-
Start cariprazine at 1.5 mg per day
All patients assigned to cariprazine started at 1.5 mg once daily. This is the studied starting dose for adjunctive use with antidepressant therapy in this trial.
-
Increase to 3 mg per day only if using the higher-dose strategy
Patients assigned to the 3 mg per day regimen were uptitrated at week 2 and then maintained on 3 mg per day through week 6. The trial therefore supports a stepwise approach rather than starting directly at 3 mg per day.
-
Assess depressive symptoms over the first 6 weeks
The primary efficacy measure in the study was the MADRS, assessed at baseline and weeks 1, 2, 4, and 6, with CGI-S and CGI-I also followed during treatment. The main trial result was negative at week 6, with no statistically significant advantage over placebo for either 1.5 mg per day or 3 mg per day, although unadjusted earlier time points numerically favored cariprazine.
-
Monitor closely for akathisia and insomnia
Akathisia and insomnia were the most common treatment-emergent adverse events occurring at least 5% and at least twice the placebo rate. Scale-derived treatment-emergent akathisia occurred in 10.8% of patients on cariprazine 1.5 mg per day and 12.0% on 3 mg per day versus 5.2% on placebo, and akathisia was the only adverse event leading to discontinuation in more than 1 patient in any group.
-
Use structured safety follow-up during treatment
The study monitored adverse events and vital signs at every visit, with electrocardiograms and laboratory testing at baseline and week 6, and serial AIMS, BARS, and SAS assessments through weeks 0 to 6. Over 6 weeks, mean weight change was less than 1 kg in all groups, weight increase of at least 7% was uncommon, no patient had a QTcF increase greater than 60 msec or QTcF above 500 msec, and no increase in treatment-emergent mania was seen with cariprazine.
Clinical Considerations
- This specific trial did not show statistically significant efficacy for adjunctive cariprazine versus placebo on the primary week-6 MADRS outcome at either 1.5 mg per day or 3 mg per day.
- Early symptom advantages favoring cariprazine were not adjusted for multiple comparisons and were therefore not statistically significant.
- Generalizability is limited because the study lasted only 6 weeks, had no active comparator, and enrolled adults aged 18 to 65 years who met strict inclusion and exclusion criteria.
- High placebo response and continued background antidepressant therapy may have reduced the ability to detect a treatment effect in this trial.
Bottom Line
If adjunctive cariprazine is used for major depressive disorder with inadequate antidepressant response, use the trial-supported sequence of 1.5 mg per day initiation with optional week-2 increase to 3 mg per day, and monitor most closely for akathisia because this study did not prove week-6 efficacy over placebo.
